Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]R. J. Linhardt: Heparin: structure and activity. Journal of medicinal chemistry 46, 2551-2564 (2003)

  • [2]H. Liu, Z. Zhang and R. J. Linhardt: Lessons learned from the contamination of heparin. Natural product reports 26, 313-321 (2009)

  • [3]R. J. Linhardt and N. S. Gunay: Production and chemical processing of low molecular weight heparins. Seminars in Thrombosis and Hemostasis 25 Suppl 3, 5-16 (1999)

  • [4]R. J. Linhardt and J. Liu: Synthetic heparin. Current opinion in pharmacology 12, 217-219 (2012)

  • [5]J. Woodcock: Introduction of Proposal for Reintroduction of Bovine Heparin to the US Market. Science Board to the Food and Drug Administration, June 4, 2014, accessed on June 18, 2015, Drug Administration, June 4, 2014, accessed on June 18, 2015, DOI: downloads/Advisory Committees/Committees Meeting Materials/Science Board to the Food and Drug Administration/UCM399418.pdf

  • [6]Z. Wang, B. Yang, Z. Zhang, M. Ly, M. Takieddin, S. Mousa, J. Liu, J. S. Dordick and R. J. Linhardt: Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Applied microbiology and biotechnology 91, 91-99 (2011)

  • [7]Y. Xu, C. Cai, K. Chandarajoti, P. H. Hsieh, L. Li, T. Q. Pham, E. M. Sparkenbaugh, J. Sheng, N. S. Key, R. Pawlinski, E. N. Harris, R. J. Linhardt and J. Liu: Homogeneous low-molecular-weight heparins with reversible anticoagulant activity. Nature Chemical Biology 10, 248-250 (2014)

  • [8]J. W. Heemskerk, E. M. Bevers and T. Lindhout: Platelet activation and blood coagulation. Thrombosis and haemostasis 88, 186-193 (2002)

  • [9]S. Palta, R. Saroa and A. Palta: Overview of the coagulation system. Indian journal of anaesthesia 58, 515-523 (2014)

  • [10]L. A. Norris: Blood coagulation. Best Practice & Research Clinical Obstetrics & Gynaecology 17, 369-383 (2003)

  • [11]E. M. Munoz and R. J. Linhardt: Heparin-binding domains in vascular biology. Arteriosclerosis, thrombosis, and vascular biology 24, 1549-1557 (2004)

  • [12]V. van Hinsbergh: Endothelium-role in regulation of coagulation and inflammation. Seminars in Immunopathology 34, 93-106 (2012)

  • [13]G. Piazza and P. M. Ridker: Is venous thromboembolism a chronic inflammatory disease? Clinical chemistry 61, 313-316 (2015)

  • [14]P. S. Wells, M. A. Forgie and M. A. Rodger: Treatment of venous thromboembolism. JAMA 311, 717-728 (2014)

  • [15]Pubmed Health: Deep Vein Thrombosis, June 11, 2014, accessed on June 18, 2015, DOI: pubmedhealth/PMH0062951/

  • [16]F. Fransson, T. Kyrk, M. Skagerlind and B. Stegmayr: Rinsing the extra corporeal circuit with a heparin and albumin solution reduces the need for systemic anticoagulant in hemodialysis. The International Journal of Artificial Organs 36, 725-729 (2013)

  • [17]F. B. Taylor, Jr., C. H. Toh, W. K. Hoots, H. Wada and M. Levi: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis and haemostasis 86, 1327-1330 (2001)

  • [18]A. Murata, K. Okamoto, T. Mayumi, K. Muramatsu and S. Matsuda: The recent time trend of outcomes of disseminated intravascular coagulation in Japan: an observational study based on a national administrative database. Journal of thrombosis and thrombolysis 38, 364-371 (2014)

  • [19]H. Wada, J. Thachil, M. Di Nisio, P. Mathew, S. Kurosawa, S. Gando, H. K. Kim, J. D. Nielsen, C. E. Dempfle, M. Levi and C. H. Toh: Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. Journal of thrombosis and haemostasis 11, 761-767 (2013)

  • [20]J. McLean: The thromboplastic action of cephalin. Am j Physiol 41, 250 (1916)

  • [21]W. I. Gonsalves, R. K. Pruthi and M. M. Patnaik: The new oral anticoagulants in clinical practice. Mayo Clinic proceedings 88, 495-511 (2013)

  • [22]C. Becattini, M. C. Vedovati and G. Agnelli: Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thrombosis research 129, 392-400 (2012)

  • [23]K. Chaudhari, B. Hamad and B. A. Syed: Antithrombotic drugs market. Nature reviews. Drug discovery 13, 571-572 (2014)

  • [24]Bayer Investor Presentation, Meet Management, Page 52, March 2013, accessed on June 12, 2015, http:DOI: securedl/1994

  • [25]J. Costin, J. Ansell, B. Laulicht, S. Bakhru and S. Steiner: Reversal agents in development for the new oral anticoagulants. Postgraduate medicine 126, 19-24 (2014)

  • [26]A. Enriquez, G. Y. Lip and A. Baranchuk: Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace In press (2015)

  • [27]Y. K. Loke, S. Pradhan, J. K. Yeong and C. S. Kwok: Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. British journal of clinical pharmacology 78, 707-717 (2014)

  • [28]J. Hirsh, T. E. Warkentin, R. Raschke, C. Granger, E. M. Ohman and J. E. Dalen: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114, 489S-510S (1998)

  • [29]J. Hirsh, S. S. Anand, J. L. Halperin, V. Fuster and A. H. Association: Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation 103, 2994-3018 (2001)

  • [30]L. Fu, G. Li, B. Yang, A. Onishi, L. Li, P. Sun, F. Zhang and R. J. Linhardt: Structural characterization of pharmaceutical heparins prepared from different animal tissues. Journal of pharmaceutical sciences 102, 1447-1457 (2013)

  • [31]J. D. D A Lane, A M Flynn, L Thunberg, and U Lindahl: Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 218, 725-732 (1984)

  • [32]S. Jonas and D. Quartermain: Low molecular weight heparin and the treatment of ischemic stroke. Animal results, the reasons for failure in human stroke trials, mechanisms of action, and the possibilities for future use in stroke. Annals of the New York Academy of Sciences 939, 268-70 (2001)

  • [33]J. Liu and L. C. Pedersen: Anticoagulant heparan sulfate: structural specificity and biosynthesis. Applied microbiology and biotechnology 74, 263-272 (2007)

  • [34]J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman and J. E. Dalen: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119, 64S-94S (2001)

  • [35]C. Wang, Z. Zhai, Y. Yang, Z. Cheng, K. Ying, L. Liang, H. Dai, K. Huang, W. Lu, Z. Zhang, X. Cheng, Y. H. Shen, B. L. Davidson and C. N. V. T. V. S. Group: Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin. The Clinical Respiratory Journal n/a-n/a (2015)

  • [36]M. Guerrini, P. A. Mourier, G. Torri and C. Viskov: Antithrombin-binding oligosaccharides: structural diversities in a unique function? Glycoconjugate Journal 31, 409-416 (2014)

  • [37]A. M. Tovar, L. A. Teixeira, S. M. Rembold, M. Leite, Jr., J. R. Lugon and P. A. Mourao: Bovine and porcine heparins: different drugs with similar effects on human haemodialysis. BMC research notes 230 (2013)

  • [38]C. I. Oie, R. Olsen, B. Smedsrod and J. B. Hansen: Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation. American journal of physiology. Gastrointestinal and liver physiology 294, G520-8 (2008)

  • [39]D. Mikhailov, H. C. Young, R. J. Linhardt and K. H. Mayo: Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. The Journal of biological chemistry 274, 25317-25329 (1999)

  • [40]Z. Liu, S. Ji, J. Sheng and F. Wang: Pharmacological effects and clinical applications of ultra low molecular weight heparins. Drug Discoveries & Therapeutics 8, 1-10 (2014)

  • [41]M. R. Lassen, O. E. Dahl, P. Mismetti, D. Destree and A. G. Turpie: AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study. Journal of thrombosis and haemostasis 7, 566-572 (2009)

  • [42]L. Hao, Q. Zhang, T. Yu, L. Yu and Y. Cheng: Modulation of ultra-low-molecular-weight heparin on (Ca2+)i in nervous cells. Brain Research Bulletin 86, 355-359 (2011)

  • [43]S. Rico, R. M. Antonijoan, I. Gich, M. Borrell, J. Fontcuberta, M. Monreal, J. Martinez-Gonzalez and M. J. Barbanoj: Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers--a first-time-in-human single ascending dose study. Thrombosis research 127, 292-298 (2011)

  • [44]R. J. Linhardt and T. Toida: Role of glycosaminoglycans in cellular communication. Accounts of chemical research 37, 431-438 (2004)

  • [45]I. Capila and R. J. Linhardt: Heparin-protein interactions. Angewandte Chemie 41, 391-412 (2002)

  • [46]D. L. Rabenstein: Heparin and heparan sulfate: structure and function. Natural product reports 19, 312-331 (2002)

  • [47]A. Ori, M. C. Wilkinson and D. G. Fernig: A systems biology approach for the investigation of the heparin/heparan sulfate interactome. The Journal of biological chemistry 286, 19892-19904 (2011)

  • [48]F. Peysselon and S. Ricard-Blum: Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. Matrix biology 35, 73-81 (2014)

  • [49]E. Kamhi, E. J. Joo, J. S. Dordick and R. J. Linhardt: Glycosaminoglycans in infectious disease. Biological reviews of the Cambridge Philosophical Society 88, 928-943 (2013)

  • [50]K. Sugahara and H. Kitagawa: Heparin and Heparan Sulfate Biosynthesis. IUBMB Life 54, 163-175 (2002)

  • [51]J. Schlessinger, A. N. Plotnikov, O. A. Ibrahimi, A. V. Eliseenkova, B. K. Yeh, A. Yayon, R. J. Linhardt and M. Mohammadi: Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Molecular cell 6, 743-750 (2000)

  • [52]L. Pellegrini, D. F. Burke, F. von Delft, B. Mulloy and T. L. Blundell: Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407, 1029-1034 (2000)

  • [53]L. Wujak, M. Didiasova, D. Zakrzewicz, H. Frey, L. Schaefer and M. Wygrecka: Heparan Sulfate Proteoglycans Mediate Factor XIIa Binding to the Cell Surface. Journal of Biological Chemistry 290, 7027-7039 (2015)

  • [54]F. Zhang, J. S. McLellan, A. M. Ayala, D. J. Leahy and R. J. Linhardt: Kinetic and structural studies on interactions between heparin or heparan sulfate and proteins of the hedgehog signaling pathway. Biochemistry 46, 3933-3941 (2007)

  • [55]R. C. Binari, B. E. Staveley, W. A. Johnson, R. Godavarti, R. Sasisekharan and A. S. Manoukian: Genetic evidence that heparin-like glycosaminoglycans are involved in wingless signaling. Development 124, 2623-2632 (1997)

  • [56]T. E. Haerry, T. R. Heslip, J. L. Marsh and M. B. O’Connor: Defects in glucuronate biosynthesis disrupt Wingless signaling in Drosophila. Development 124, 3055-3064 (1997)

  • [57]X. Lin and N. Perrimon: Dally cooperates with Drosophila Frizzled 2 to transduce Wingless signalling. Nature 400, 281-284 (1999)

  • [58]S. L. Bullock, J. M. Fletcher, R. S. Beddington and V. A. Wilson: Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes & development 12, 1894-1906 (1998)

  • [59]X. Lin, G. Wei, Z. Shi, L. Dryer, J. D. Esko, D. E. Wells and M. M. Matzuk: Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Developmental biology 224, 299-311 (2000)

  • [60]D. Stickens, B. M. Zak, N. Rougier, J. D. Esko and Z. Werb: Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development 132, 5055-5068 (2005)

  • [61]C. R. Holst, H. Bou-Reslan, B. B. Gore, K. Wong, D. Grant, S. Chalasani, R. A. Carano, G. D. Frantz, M. Tessier-Lavigne, B. Bolon, D. M. French and A. Ashkenazi: Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS ONE 2, e575 (2007)

  • [62]R. Castelli, F. Porro and P. Tarsia: The heparins and cancer: review of clinical trials and biological properties. Vascular medicine 9, 205-213 (2004)

  • [63]N. M. Kuderer, A. A. Khorana, G. H. Lyman and C. W. Francis: A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110, 1149-1161 (2007)

  • [64]L. Bergamaschini, E. Rossi, C. Vergani and M. G. De Simoni: Alzheimer’s disease: another target for heparin therapy. TheScientificWorldJournal 9, 891-908 (2009)

  • [65]A. T. Cohen, M. Dobromirski and M. M. P. Gurwith: Managing pulmonary embolism from presentation to extended treatment. Thrombosis Research 133, 139-148 (2014)

  • [66]S. V. Konstantinides: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European heart journal 35, 3145-3146 (2014)

  • [67]C. Kearon, L. Harrison, M. Crowther and J. S. Ginsberg: Optimal Dosing of Subcutaneous Unfractionated Heparin for the Treatment of Deep Vein Thrombosis. Thrombosis Research 97, 395-403 (2000)

  • [68]N. K.: Low-molecular-weight heparins and angiogenesis. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 114, 79-102 (2006)

  • [69]H. S. Amane and N. P. Burte: A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris. Indian journal of pharmacology 43, 703-706 (2011)

  • [70]A. Undas, K. Szułdrzyński, K. E. Brummel-Ziedins, W. Tracz, K. Zmudka and K. G. Mann: Systemic blood coagulation activation in acute coronary syndromes. Blood 113, 2070-2078 (2009)

  • [71]J. D. Rich, J. M. Maraganore, E. Young, R.-M. Lidon, B. Adelman, P. Bourdon, S. Charenkavanich, J. Hirsh, P. Theroux and C. P. Cannon: Heparin resistance in acute coronary syndromes. Journal of Thrombosis and Thrombolysis 23, 93-100 (2007)

  • [72]D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin and W. J. Manning: Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 429S-456S (2004)

  • [73]C. A. Ciervo, C. B. Granger and F. A. Schaller: Stroke prevention in patients with atrial fibrillation: disease burden and unmet medical needs. The Journal of the American Osteopathic Association 112, eS2-8 (2012)

  • [74]K. E. B. A. J. I. JENSEN: Inhaled heparin is effective in exacerbations of asthma. Respiratory Medicine 94, 174-175 (2000)

  • [75]Z. Diamant and C. P. Page: Heparin and related molecules as a new treatment for asthma. Pulmonary pharmacology & therapeutics 13, 1-4 (2000)

  • [76]H. W. C. Richard J. Martin, Joyce M. Honour, and Ronald J. Harbeck: Airway Inflammation and Bronchial Hyperresponsiveness after Mycoplasma pneumoniae Infection in a Murine Model. American Journal of Respiratory Cell and Molecular Biology 24, 249-254 (2001)

  • [77]Y. M. Al Suleimani, Y. Dong and M. J. Walker: Differential responses to various classes of drugs in a model of allergic rhinitis in guinea pigs. Pulmonary pharmacology & therapeutics 21, 340-348 (2008)

  • [78]Pfizer Inc.: Heparin Sodium Injection Official Label, Revised July, 2011

  • [79]Sanofi-aventis: Lovenox (enoxaparin sodium injection) Official Label, Revised October, 2013

  • [80]ASPEN NDB: Arixtra (fondaparinux sodium) Official Label, Revised July, 2014

  • [81]G. M. Lee and G. M. Arepally: Heparin-induced thrombocytopenia. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 668-674 (2013)

  • [82]A. Cuker, G. Arepally, M. A. Crowther, L. Rice, F. Datko, K. Hook, K. J. Propert, D. J. Kuter, T. L. Ortel, B. A. Konkle and D. B. Cines: The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. Journal of thrombosis and haemostasis 8, 2642-2650 (2010)

  • [83]N. Martel, J. Lee and P. S. Wells: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106, 2710-2715 (2005)

  • [84]K. Panday, A. Gona and M. B. Humphrey: Medication-induced osteoporosis: screening and treatment strategies. Therapeutic advances in musculoskeletal disease 6, 185-202 (2014)

  • [85]G. Matziolis, C. Perka, A. Disch and H. Zippel: Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcified tissue international 73, 370-379 (2003)

  • [86]A. E. Handschin, O. A. Trentz, S. P. Hoerstrup, H. J. Kock, G. A. Wanner and O. Trentz: Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. The British journal of surgery 92, 177-183 (2005)

  • [87]D. Barboza: Virus Spreading Alarm and Pig Disease in China. New York Times, August 16, 2007, accessed on June 19, 2015. DOI: 2007/08/16/business/worldbusiness/16pigs.html?pagewanted=all

  • [88]J. E. Butler, K. M. Lager, W. Golde, K. S. Faaberg, M. Sinkora, C. Loving and Y. I. Zhang: Porcine reproductive and respiratory syndrome (PRRS): an immune dysregulatory pandemic. Immunologic research 59, 81-108 (2014)

  • [89]K. Jung and L. J. Saif: Porcine epidemic diarrhea virus infection: Etiology, epidemiology, pathogenesis and immunoprophylaxis. Veterinary journal 204, 134-143 (2015)

  • [90]G. R. Santos, A. M. Tovar, N. V. Capille, M. S. Pereira, V. H. Pomin and P. A. Mourao: Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs. Drug discovery today 19, 1801-1807 (2014)

  • [91]U. Bhaskar, E. Sterner, A. M. Hickey, A. Onishi, F. Zhang, J. S. Dordick and R. J. Linhardt: Engineering of routes to heparin and related polysaccharides. Applied microbiology and biotechnology 93, 1-16 (2012)

  • [92]U. Bhaskar. 2014. “Chemoenzymatic synthesis of heparin for a safer bioengineered alternative.” PhD dissertation, Rensselaer Polytechnic Institute.

  • [93]Z. Wang, M. Ly, F. Zhang, W. Zhong, A. Suen, A. M. Hickey, J. S. Dordick and R. J. Linhardt: E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnology and bioengineering 107, 964-973 (2010)

  • [94]Z. Wang, J. S. Dordick and R. J. Linhardt: Escherichia coli K5 heparosan fermentation and improvement by genetic engineering. Bioengineered bugs 2, 63-67 (2011)

  • [95]B. F. Cress, Z. R. Greene, R. J. Linhardt and M. A. Koffas: Draft Genome Sequence of Escherichia coli Strain ATCC 23506 (Serovar O10:K5:H4). Genome announcements, 1, e0004913 (2013)

  • [96]Z. Wang, J. Li, S. Cheong, U. Bhaskar, O. Akihiro, F. Zhang, J. S. Dordick and R. J. Linhardt: Response surface optimization of the heparosan N-deacetylation in producing bioengineered heparin. Journal of biotechnology 156, 188-196 (2011)

  • [97]O. F. Restaino, U. Bhaskar, P. Paul, L. Li, M. De Rosa, J. S. Dordick and R. J. Linhardt: High cell density cultivation of a recombinant E. coli strain expressing a key enzyme in bioengineered heparin production. Applied microbiology and biotechnology 97, 3893-3900 (2013)

  • [98]J. Zhang, M. Suflita, C. M. Fiaschetti, G. Li, L. Li, F. Zhang, J. S. Dordick and R. J. Linhardt: High cell density cultivation of a recombinant Escherichia coli strain expressing a 6-O-sulfotransferase for the production of bioengineered heparin. Journal of applied microbiology 118, 92-98 (2015)

  • [99]J. Zhang, M. Suflita, G. Li, W. Zhong, L. Li, J. S. Dordick, R. J. Linhardt and F. Zhang: High cell density cultivation of recombinant Escherichia coli strains expressing 2-O-sulfotransferase and C5-epimerase for the production of bioengineered heparin. Applied Biochemistry and Biotechnology 175, 2986-2995 (2015)

  • [100]J. Suwan, A. Torelli, A. Onishi, J. S. Dordick and R. J. Linhardt: Addressing endotoxin issues in bioengineered heparin. Biotechnology and applied biochemistry 59, 420-428 (2012)

  • [101]J. Xiong, U. Bhaskar, G. Li, L. Fu, L. Li, F. Zhang, J. S. Dordick and R. J. Linhardt: Immobilized enzymes to convert N-sulfo, N-acetyl heparosan to a critical intermediate in the production of bioengineered heparin. Journal of biotechnology 167, 241-247 (2013)

  • [102]U. Bhaskar, G. Li, L. Fu, A. Onishi, M. Suflita, J. S. Dordick and R. J. Linhardt: Combinatorial one-pot chemoenzymatic synthesis of heparin. Carbohydrate Polymers 122, 399-407 (2014)

  • [103]P. A. Driguez, P. Potier and P. Trouilleux: Synthetic oligosaccharides as active pharmaceutical ingredients: lessons learned from the full synthesis of one heparin derivative on a large scale. Natural product reports 31, 980-989 (2014)

  • [104]J. Liu and R. J. Linhardt: Chemoenzymatic synthesis of heparan sulfate and heparin. Natural product reports 31, 1676-1685 (2014)

  • [105]Y. Xu, S. Masuko, M. Takieddin, H. Xu, R. Liu, J. Jing, S. A. Mousa, R. J. Linhardt and J. Liu: Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science 334, 498-501 (2011)

  • [106]Y. Xu, E. H. Pempe and J. Liu: Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities. The Journal of biological chemistry 287, 29054-29061 (2012)

  • [107]S. U. Hansen, G. J. Miller, C. Cole, G. Rushton, E. Avizienyte, G. C. Jayson and J. M. Gardiner: Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies. Nature Communications, 4 (2013)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Review
Heparin and anticoagulation
Akihiro Onishi 1, Kalib St Ange 1, Jonathan S. Dordick 1, Robert J. Linhardt 1,*
Affiliation
Article Info

1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8 St, Troy, NY 12180 USA

Abstract

Heparin, a sulfated polysaccharide, has been used as a clinical anticoagulant for over 90 years. Newer anticoagulants, introduced for certain specialized applications, have not significantly displaced heparin and newer heparin-based anticoagulants in most medical procedures. This chapter, while reviewing anticoagulation and these newer anticoagulants, focuses on heparin-based anticoagulants, including unfractionated heparin, low molecular weight heparins and ultra-low molecular weight heparins. Heparin’s structures and its biological and therapeutic roles are discussed. Particular emphasis is placed on heparin’s therapeutic application and its adverse effects. The future prospects are excellent for new heparins and new heparin-based therapeutics with improved properties.

Keywords

  • Heparin
  • Anticoagulation
  • Anticoagulants
  • Bovine Heparin
  • Bioengineered Heparin
  • Review

References